SI-BONE (SIBN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.09
- Estimate
- -$0.15
- Surprise
- +39.9%
- Score today
- 5.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
SI-BONE (SIBN) reported a narrower loss than forecast — diluted EPS of -$0.09 against the -$0.15 estimate (a 39.9% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SIBN Sell at 5.8/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +39.9% surprise compares with a +47.3% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Quality below floor (3.4 < 4.0)
- Value-trap signals (2/5): Revenue declining (-7.6% YoY), Margin compression (op margin -142.6%)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $18.54
- Price target
- $21.75
- Stop
- $17.45
- Upside to target
- +17.3%
- Reward-to-risk
- 2.5:1
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
SIBN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $831.4M
- P/E (fwd)
- -56.1
- 52-week range
- $11.48–$21.89
- Off 52-week high
- 15.3%
- RSI (14)
- 32
- Volume vs avg
- 0.73×
- Score today
- 5.8/10